Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 119

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Telomeres and telomerase in oncogenesis (Review)

Trybek, Tomasz, Kowalik, Artur, Góźdź, Stanisław, Kowalska, Aldona·2020·Oncology Letters
DOI 10.3892/ol.2020.11659PMC PMC7377093
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2020.11659

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Telomere structure. Telomeric DNA contains tandem repeats of DNA sequence 5′-TTAGGG-3′, terminal 3′ G-rich overhang and shelterin complex of six subunits: TRF1, TRF2 and POT1 (proteins responsible for recognition of TTAGGG telomeric repeats), and TIN2, TPP1 and RAP1 (complex stabilizing proteins). The telomere structure forms two loops, the T-loop and the D-loop. TRF1, telomere repeat factor-1; TRF2, telomere repeat factor-2; POT1, protection of telomeres-1; TIN2, TRF1 interacting protein-2; RAP1, repressor/activator protein 1; TPP1, TINT1/PTOP/PIP1 protein (POT1-TIN2 organizing protein).
Figure 1. Telomere structure. Telomeric DNA contains tandem repeats of DNA sequence 5′-TTAGGG-3′, terminal 3′ G-rich overhang and shelterin complex of six subunits: TRF1, TRF2 and POT1 (proteins responsible for recognition of TTAGGG telomeric repeats), and TIN2, TPP1 and RAP1 (complex stabilizing proteins). The telomere structure forms two loops, the T-loop and the D-loop. TRF1, telomere repeat factor-1; TRF2, telomere repeat factor-2; POT1, protection of telomeres-1; TIN2, TRF1 interacting protein-2; RAP1, repressor/activator protein 1; TPP1, TINT1/PTOP/PIP1 protein (POT1-TIN2 organizing protein).CC BY-NC-ND · PubMed Central
Figure 2. Telomerase structure. Human telomerase is composed of TERC-telomerase RNA component (RNA template), TERT-telomerase reverse transcriptase (catalytic subunit with reverse transcriptase activity) and the accessory proteins. NHP2, non-histone protein 2; NOP10, nucleolar protein 10; GAR1, glycine arginine rich 1; TCAB1, telomerase Cajal body protein 1; HSP90, heat shock protein 90; SRSF11, serine and arginine rich splicing factor 11; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase.
Figure 2. Telomerase structure. Human telomerase is composed of TERC-telomerase RNA component (RNA template), TERT-telomerase reverse transcriptase (catalytic subunit with reverse transcriptase activity) and the accessory proteins. NHP2, non-histone protein 2; NOP10, nucleolar protein 10; GAR1, glycine arginine rich 1; TCAB1, telomerase Cajal body protein 1; HSP90, heat shock protein 90; SRSF11, serine and arginine rich splicing factor 11; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase.CC BY-NC-ND · PubMed Central
Figure 3. Frequency of TERT promoter mutations in different types of cancer. Data were obtained from a previous study (37). TERT, telomerase reverse transcriptase; PDC, poorly differentiated carcinoma.
Figure 3. Frequency of TERT promoter mutations in different types of cancer. Data were obtained from a previous study (37). TERT, telomerase reverse transcriptase; PDC, poorly differentiated carcinoma.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 123

  1. [2]Seluanov A Gladyshev VN Vijg J Gorbunova V Mechanisms of cancer resistance in long-lived mammals Nat Rev Cancer 18 433 441 2018 10.1038/s41568-018-0004-9 29622806 PMC6015544 · DOI
  2. [4]Liu T Yuan X Xu D Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: Biological and clinical implications Genes (Basel) 7 pii E38 2016 10.3390/genes7070038 27438857 PMC4962008 · DOI
  3. [5]Yuan X Larsson C Xu D Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players Oncogene 38 6172 6183 2019 10.1038/s41388-019-0872-9 31285550 PMC6756069 · DOI · Paper page
  4. [6]Dilley RL Greenberg RA ALTernative telomere maintenance and cancer Trends Cancer 1 145 156 2015 10.1016/j.trecan.2015.07.007 26645051 PMC4669901 · DOI
  5. [7]Hayflick L The limited in vitro lifetime of human diploid cell strains Exp Cell Res 37 614 636 1965 10.1016/0014-4827(65)90211-9 14315085 · DOI · Paper page
  6. [8]Olovnikov AM A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon J Theor Biol 41 181 190 1973 10.1016/0022-5193(73)90198-7 4754905 · DOI
  7. [9]Szostak JW Blackburn EH Cloning yeast telomeres on linear plasmid vectors Cell 29 245 255 1982 10.1016/0092-8674(82)90109-X 6286143 · DOI
  8. [10]Blackburn EH Structure and function of telomeres Nature 350 569 573 1991 10.1038/350569a0 1708110 · DOI · Paper page
  9. [11]Greider CW Telomerase is processive Mol Cell Biol 11 4572 4580 1991 10.1128/MCB.11.9.4572 1875940 PMC361337 · DOI
  10. [12]Moyzis RK Buckingham JM Cram LS Dani M Deaven LL Jones MD Meyne J Ratliff RL Wu JR A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes Proc Natl Acad Sci USA 85 6622 6626 1988 10.1073/pnas.85.18.6622 3413114 PMC282029 · DOI · Paper page
  11. [13]Makarov VL Hirose Y Langmore JP Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening Cell 88 657 666 1997 10.1016/S0092-8674(00)81908-X 9054505 · DOI
  12. [14]Wellinger RJ Sen D The DNA structures at the ends of eukaryotic chromosomes Eur J Cancer 33 735 749 1997 10.1016/S0959-8049(97)00067-1 9282112 · DOI
  13. [15]Blackburn EH Switching and signaling at the telomere Cell 106 661 673 2001 10.1016/S0092-8674(01)00492-5 11572773 · DOI
  14. [17]Lendvay TS Morris DK Sah J Balasubramanian B Lundblad V Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes Genetics 144 1399 1412 1996 8978029 PMC1207693
  15. [18]Lingner J Cech TR Purification of telomerase from Euplotes aediculatus: Requirement of a primer 3′ overhang Proc Natl Acad Sci USA 93 10712 10717 1996 10.1073/pnas.93.20.10712 8855245 PMC38220 · DOI
  16. [19]Liu L Lai S Andrews LG Tollefsbol TO Genetic and epigenetic modulation of telomerase activity in development and disease Gene 340 1 10 2004 10.1016/j.gene.2004.06.011 15556289 · DOI
  17. [22]Horn S Figl A Rachakonda PS Fischer C Sucker A Gast A Kadel S Moll I Nagore E Hemminki K TERT promoter mutations in familial and sporadic melanoma Science 339 959 961 2013 10.1126/science.1230062 23348503 · DOI · Paper page
  18. [23]Huang FW Hodis E Xu MJ Kryukov GV Chin L Garraway LA Highly recurrent TERT promoter mutations in human melanoma Science 339 957 959 2013 10.1126/science.1229259 23348506 PMC4423787 · DOI · Paper page
  19. [24]Zimmermann M Kibe T Kabir S de Lange T TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling Genes Dev 28 2477 2491 2014 10.1101/gad.251611.114 25344324 PMC4233241 · DOI
  20. [25]Arnoult N Karlseder J Complex interactions between the DNA-damage response and mammalian telomeres Nat Struct Mol Biol 22 859 866 2015 10.1038/nsmb.3092 26581520 PMC4739752 · DOI · Paper page
  21. [27]Janoušková E Nečasová I Pavloušková J Zimmermann M Hluchý M Marini V Nováková M Hofr C Human Rap1 modulates TRF2 attraction to telomeric DNA Nucleic Acids Res 43 2691 2700 2015 10.1093/nar/gkv097 25675958 PMC4357705 · DOI
  22. [28]Frescas D de Lange T TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1 Mol Cell Biol 34 1349 1362 2014 10.1128/MCB.01052-13 24469404 PMC3993560 · DOI
  23. [29]Stewart JA Chaiken MF Wang F Price CM Maintaining the end: Roles of telomere proteins in end-protection, telomere replication and length regulation Mutat Res 730 12 19 2012 10.1016/j.mrfmmm.2011.08.011 21945241 PMC3256267 · DOI
  24. [30]Martínez P Blasco MA Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins Nat Rev Cancer 11 161 176 2011 10.1038/nrc3025 21346783 · DOI · Paper page
  25. [31]Kowalska A Kowalik A Telomeres and telomerase in oncogenesis Contemp Oncol (Pozn) 10 485 496 2006 PMC7377093 32724340
  26. [32]Shore D Bianchi A Telomere length regulation: Coupling DNA end processing to feedback regulation of telomerase EMBO J 28 2309 2322 2009 10.1038/emboj.2009.195 19629031 PMC2722252 · DOI
  27. [33]Bourgeron T Xu Z Doumic M Teixeira MT The asymmetry of telomere replication contributes to replicative senescence heterogeneity Sci Rep 5 15326 2015 10.1038/srep15326 26468778 PMC4606794 · DOI
  28. [35]Pedram M Sprung CN Gao Q Lo AWI Reynolds GE Murnane JP Telomere position effect and silencing of transgenes near telomeres in the mouse Mol Cell Biol 26 1865 1878 2006 10.1128/MCB.26.5.1865-1878.2006 16479005 PMC1430234 · DOI
  29. [36]Robin JD Ludlow AT Batten K Magdinier F Stadler G Wagner KR Shay JW Wright WE Telomere position effect: Regulation of gene expression with progressive telomere shortening over long distances Genes Dev 28 2464 2476 2014 10.1101/gad.251041.114 25403178 PMC4233240 · DOI
  30. [38]Kyo S Takakura M Fujiwara T Inoue M Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers Cancer Sci 99 1528 1538 2008 10.1111/j.1349-7006.2008.00878.x 18754863 PMC11158053 · DOI · Paper page
  31. [39]Kang SS Kwon T Kwon DY Do SI Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit J Biol Chem 274 13085 13090 1999 10.1074/jbc.274.19.13085 10224060 · DOI
  32. [40]Broccoli D Young JW de Lange T Telomerase activity in normal and malignant hematopoietic cells Proc Natl Acad Sci USA 92 9082 9086 1995 10.1073/pnas.92.20.9082 7568077 PMC40928 · DOI · Paper page
  33. [41]Härle-Bachor C Boukamp P Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes Proc Natl Acad Sci USA 93 6476 6481 1996 10.1073/pnas.93.13.6476 8692840 PMC39048 · DOI
  34. [42]Kyo S Takakura M Kohama T Inoue M Telomerase activity in human endometrium Cancer Res 57 610 614 1997 9044835
  35. [45]Cesare AJ Reddel RR Alternative lengthening of telomeres: Models, mechanisms and implications Nat Rev Genet 11 319 330 2010 10.1038/nrg2763 20351727 · DOI
  36. [47]Henson JD Hannay JA McCarthy SW Royds JA Yeager TR Robinson RA Wharton SB Jellinek DA Arbuckle SM Yoo J A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas Clin Cancer Res 11 217 225 2005 15671549
  37. [48]Im E Yoon JB Lee HW Chung KC Human telomerase reverse transcriptase (hTERT) positively regulates 26s proteasome activity J Cell Physiol 232 2083 2093 2017 10.1002/jcp.25607 27648923 · DOI
  38. [49]Hu C Ni Z Li BS Yong X Yang X Zhang JW Zhang D Qin Y Jie MM Dong H hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation Gut 66 31 42 2017 10.1136/gutjnl-2015-309322 26370108 · DOI
  39. [50]Saretzki G Extra-telomeric functions of human telomerase: Cancer, mitochondria and oxidative stress Curr Pharm Des 20 6386 6403 2014 10.2174/1381612820666140630095606 24975608 · DOI
  40. [51]Masutomi K Possemato R Wong JM Currier JL Tothova Z Manola JB Ganesan S Lansdorp PM Collins K Hahn WC The telomerase reverse transcriptase regulates chromatin state and DNA damage responses Proc Natl Acad Sci USA 102 8222 8227 2005 10.1073/pnas.0503095102 15928077 PMC1149439 · DOI
  41. [53]Zhang K Guo Y Wang X Zhao H Ji Z Cheng C Li L Fang Y Xu D Zhu HH Gao WQ WNT/β-catenin directs self-renewal symmetric cell division of hTERThigh prostate cancer stem cells Cancer Res 77 2534 2547 2017 10.1158/0008-5472.CAN-16-1887 28209613 · DOI
  42. [54]Ding D Xi P Zhou J Wang M Cong YS Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-κB-dependent transcription FASEB J 27 4375 4383 2013 10.1096/fj.13-230904 23884427 · DOI
  43. [55]Lassmann T Maida Y Tomaru Y Yasukawa M Ando Y Kojima M Kasim V Simon C Daub CO Carninci P Telomerase reverse transcriptase regulates microRNAs Int J Mol Sci 16 1192 1208 2015 10.3390/ijms16011192 25569094 PMC4307298 · DOI
  44. [56]Drevytska TI Nagibin VS Gurianova VL Kedlyan VR Moibenko AA Dosenko VE Silencing of TERT decreases levels of miR-1, miR-21, miR-29a and miR-208a in cardiomyocytes Cell Biochem Funct 32 565 570 2014 10.1002/cbf.3051 25156787 · DOI
  45. [57]Koh CM Khattar E Leow SC Liu CY Muller J Ang WX Li Y Franzoso G Li S Guccione E Tergaonkar V Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity J Clin Invest 125 2109 2122 2015 10.1172/JCI79134 25893605 PMC4463203 · DOI
  46. [58]Mattiussi M Tilman G Lenglez S Decottignies A Human telomerase represses ROS-dependent cellular responses to tumor necrosis factor-α without affecting NF-κB activation Cell Signal 24 708 717 2012 10.1016/j.cellsig.2011.11.004 22108091 · DOI
  47. [60]Zhang Y Toh L Lau P Wang X Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer J Biol Chem 287 32494 32511 2012 10.1074/jbc.M112.368282 22854964 PMC3463325 · DOI
  48. [61]Cong YS Wen J Bacchetti S The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter Hum Mol Genet 8 137 142 1999 10.1093/hmg/8.1.137 9887342 · DOI
  49. [62]Lee DD Leão R Komosa M Gallo M Zhang CH Lipman T Remke M Heidari A Nunes NM Apolónio JD DNA hypermethylation within TERT promoter upregulates TERT expression in cancer J Clin Invest 129 223 229 2019 10.1172/JCI128527 30358567 PMC6307937 · DOI
  50. [63]Casillas MA Brotherton SL Andrews LG Ruppert JM Tollefsbol TO Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements Gene 316 57 65 2003 10.1016/S0378-1119(03)00739-X 14563552 · DOI · Paper page
  51. [64]Bellon M Nicot C Regulation of telomerase and telomeres: Human tumor viruses take control J Natl Cancer Inst 100 98 108 2008 10.1093/jnci/djm269 18182620 · DOI
  52. [66]Killela PJ Reitman ZJ Jiao Y Bettegowda C Agrawal N Diaz LA Jr Friedman AH Friedman H Gallia GL Giovanella BC TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal Proc Natl Acad Sci USA 110 6021 6026 2013 10.1073/pnas.1303607110 23530248 PMC3625331 · DOI · Paper page
  53. [67]Rachakonda PS Hosen I de Verdier PJ Fallah M Heidenreich B Ryk C Wiklund NP Steineck G Schadendorf D Hemminki K Kumar R TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism Proc Natl Acad Sci USA 110 17426 17431 2013 10.1073/pnas.1310522110 24101484 PMC3808633 · DOI
  54. [68]Wang K Liu T Liu L Liu J Liu C Wang C Ge N Ren H Yan K Hu S TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas Oncotarget 5 1829 1836 2014 10.18632/oncotarget.1829 24742867 PMC4039120 · DOI
  55. [69]Cevik D Yildiz G Ozturk M Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations World J Gastroenterol 21 311 317 2015 10.3748/wjg.v21.i1.311 25574106 PMC4284350 · DOI
  56. [70]Liu X Bishop J Shan Y Pai S Liu D Murugan AK Sun H El-Naggar AK Xing M Highly prevalent TERT promoter mutations in aggressive thyroid cancers Endocr Relat Cancer 20 603 610 2013 10.1530/ERC-13-0210 23766237 PMC3782569 · DOI
  57. [71]Koelsche C Renner M Hartmann W Brandt R Lehner B Waldburger N Alldinger I Schmitt T Egerer G Penzel R TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities J Exp Clin Cancer Res 33 33 2014 10.1186/1756-9966-33-33 24726063 PMC4022359 · DOI
  58. [72]Vinagre J Pinto V Celestino R Reis M Pópulo H Boaventura P Melo M Catarino T Lima J Lopes JM Telomerase promoter mutations in cancer: An emerging molecular biomarker? Virchows Arch 465 119 133 2014 10.1007/s00428-014-1608-4 25048572 · DOI
  59. [74]Chen X Kost J Sulovari A Wong N Liang WS Cao J Li D A virome-wide clonal integration analysis platform for discovering cancer viral etiology Genome Res 29 819 830 2019 10.1101/gr.242529.118 30872350 PMC6499315 · DOI
  60. [75]Strååt K Liu C Rahbar A Zhu Q Liu L Wolmer-Solberg N Lou F Liu Z Shen J Jia J Activation of telomerase by human cytomegalovirus J Natl Cancer Inst 101 488 497 2009 10.1093/jnci/djp031 19318640 · DOI
  61. [76]Labgaa I Villacorta-Martin C D'Avola D Craig AJ von Felden J Martins-Filho SN Sia D Stueck A Ward SC Fiel MI A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma Oncogene 37 3740 3752 2018 10.1038/s41388-018-0206-3 29628508 PMC6035113 · DOI
  62. [77]Hurst CD Platt FM Knowles MA Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine Eur Urol 65 367 369 2014 10.1016/j.eururo.2013.08.057 24035680 · DOI
  63. [78]Juratli TA Stasik S Zolal A Schuster C Richter S Daubner D Juratli MA Thowe R Hennig S Makina M TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: A pilot prospective study Clin Cancer Res 24 5282 5291 2018 10.1158/1078-0432.CCR-17-3717 29941484 · DOI
  64. [79]Liu L Liu C Fotouhi O Fan Y Wang K Xia C Shi B Zhang G Wang K Kong F TERT promoter hypermethylation in gastrointestinal cancer: A potential stool biomarker Oncologist 22 1178 1188 2017 10.1634/theoncologist.2017-0064 28754720 PMC5634768 · DOI
  65. [80]Bougel S Lhermitte B Gallagher G de Flaugergues JC Janzer RC Benhattar J Methylation of the hTERT promoter: A novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids Clin Cancer Res 19 2216 2223 2013 10.1158/1078-0432.CCR-12-1246 23444211 · DOI
  66. [81]Bianchi F Nicassio F Marzi M Belloni E Dall'olio V Bernard L Pelosi G Maisonneuve P Veronesi G Di Fiore PP A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer EMBO Mol Med 3 495 503 2011 10.1002/emmm.201100154 21744498 PMC3377091 · DOI
  67. [82]Nagore E Heidenreich B Rachakonda S Garcia-Casado Z Requena C Soriano V Frank C Traves V Quecedo E Sanjuan-Gimenez J TERT promoter mutations in melanoma survival Int J Cancer 139 75 84 2016 10.1002/ijc.30042 26875008 PMC8238633 · DOI
  68. [83]Yuan Y Qi C Maling G Xiang W Yanhui L Ruofei L Yunhe M Jiewen L Qing M TERT mutation in glioma: Frequency, prognosis and risk J Clin Neurosci 26 57 62 2016 10.1016/j.jocn.2015.05.066 26765760 · DOI
  69. [84]Melo M da Rocha AG Vinagre J Batista R Peixoto J Tavares C Celestino R Almeida A Salgado C Eloy C TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas J Clin Endocrinol Metab 99 E754 765 2014 10.1210/jc.2013-3734 24476079 PMC4191548 · DOI
  70. [85]Liu R Xing M TERT promoter mutations in thyroid cancer Endocr Relat Cancer 23 R143 R155 2016 10.1530/ERC-15-0533 26733501 PMC4750651 · DOI
  71. [86]Castelo-Branco P Choufani S Mack S Gallagher D Zhang C Lipman T Zhukova N Walker EJ Martin D Merino D Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study Lancet Oncol 14 534 542 2013 10.1016/S1470-2045(13)70110-4 23598174 · DOI
  72. [87]Svahn F Paulsson JO Stenman A Fotouhi O Mu N Murtha TD Korah R Carling T Bäckdahl M Wang N TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma Int J Mol Med 42 1675 1683 2018 29956721
  73. [88]Liu X Qu S Liu R Sheng C Shi X Zhu G Murugan AK Guan H Yu H Wang Y TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer J Clin Endocrinol Metab 99 E1130 E1136 2014 10.1210/jc.2013-4048 24617711 PMC4037723 · DOI
  74. [89]Macerola E Loggini B Giannini R Garavello G Giordano M Proietti A Niccoli C Basolo F Fontanini G Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness Virchows Arch 467 177 184 2015 10.1007/s00428-015-1784-x 26055532 · DOI
  75. [90]Liu R Zhang T Zhu G Xing M Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer Nat Commun 9 579 2018 10.1038/s41467-018-03033-1 29422527 PMC5805723 · DOI
  76. [91]Liu W Yin Y Wang J Shi B Zhang L Qian D Li C Zhang H Wang S Zhu J Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC Oncotarget 8 179 190 2017 10.18632/oncotarget.10162 27329725 PMC5352098 · DOI
  77. [92]Meeker AK Hicks JL Platz EA March GE Bennett CJ Delannoy MJ De Marzo AM Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis Cancer Res 62 6405 6409 2002 12438224
  78. [93]Pestana A Vinagre J Sobrinho-Simões M Soares P TERT biology and function in cancer: Beyond immortalisation J Mol Endocrinol 58 R129 R146 2017 10.1530/JME-16-0195 28057768 · DOI
  79. [94]Frink RE Peyton M Schiller JH Gazdar AF Shay JW Minna JD Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner Oncotarget 7 31639 31651 2016 10.18632/oncotarget.9335 27192120 PMC5077965 · DOI
  80. [95]Chiappori AA Kolevska T Spigel DR Hager S Rarick M Gadgeel S Blais N Von Pawel J Hart L Reck M A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer Ann Oncol 26 354 362 2015 10.1093/annonc/mdu550 25467017 PMC4304381 · DOI
  81. [96]Burchett KM Yan Y Ouellette MM Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells PLoS One 9 e85155 2014 10.1371/journal.pone.0085155 24409321 PMC3883701 · DOI
  82. [97]Shammas MA Koley H Bertheau RC Neri P Fulciniti M Tassone P Blotta S Protopopov A Mitsiades C Batchu RB Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo Leukemia 22 1410 1418 2008 10.1038/leu.2008.81 18449204 PMC3155939 · DOI
  83. [99]Tokcaer-Keskin Z Dikmen ZG Ayaloglu-Butun F Gultekin S Gryaznov SM Akcali KC The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6 Stem Cell Rev Rep 6 224 233 2010 10.1007/s12015-010-9124-7 20180048 · DOI
  84. [100]Burchett KM Etekpo A Batra SK Yan Y Ouellette MM Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells Oncotarget 8 83754 83767 2017 10.18632/oncotarget.19410 29137380 PMC5663552 · DOI
  85. [101]Koziel JE Herbert BS The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells Breast Cancer Res Treat 149 607 618 2015 10.1007/s10549-015-3270-1 25627551 PMC4667948 · DOI
  86. [102]Wu X Zhang J Yang S Kuang Z Tan G Yang G Wei Q Guo Z Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma Oncotarget 8 13600 13619 2017 10.18632/oncotarget.14618 28099140 PMC5355123 · DOI
  87. [103]Chhabra G Wojdyla L Frakes M Schrank Z Leviskas B Ivancich M Vinay P Ganapathy R Ramirez BE Puri N Mechanism of action of G-quadruplex-forming oligonucleotide homologous to the telomere overhang in melanoma J Invest Dermatol 138 903 910 2018 10.1016/j.jid.2017.11.021 29203363 · DOI
  88. [104]Schrank Z Khan N Osude C Singh S Miller RJ Merrick C Mabel A Kuckovic A Puri N Oligonucleotides targeting telomeres and telomerase in cancer Molecules 23 pii E2267 2018 10.3390/molecules23092267 30189661 PMC6225148 · DOI
  89. [105]Pitman RT Wojdyla L Puri N Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma Oncotarget 4 761 771 2013 10.18632/oncotarget.1047 23800953 PMC3742836 · DOI
  90. [106]Puri N Pitman RT Mulnix RE Erickson T Iness AN Vitali C Zhao Y Salgia R Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides Cancer Lett 343 14 23 2014 10.1016/j.canlet.2013.09.010 24041868 PMC5839143 · DOI
  91. [107]Wojdyla L Stone AL Sethakorn N Uppada SB Devito JT Bissonnette M Puri N T-oligo as an anticancer agent in colorectal cancer Biochem Biophys Res Commun 446 596 601 2014 10.1016/j.bbrc.2014.03.013 24632202 PMC4843172 · DOI
  92. [108]Weng D Cunin MC Song B Price BD Eller MS Gilchrest BA Calderwood SK Gong J Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment Breast Cancer Res 12 R71 2010 10.1186/bcr2639 20846433 PMC3096958 · DOI
  93. [109]Guzman H Sanders K Idica A Bochnakian A Jury D Daugaard I Zisoulis DG Pedersen IM miR-128 inhibits telomerase activity by targeting TERT mRNA Oncotarget 9 13244 13253 2018 10.18632/oncotarget.24284 29568354 PMC5862575 · DOI
  94. [110]Zhou N Fei D Zong S Zhang M Yue Y MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer Oncol Lett 12 3633 3639 2016 10.3892/ol.2016.5038 27900047 PMC5104143 · DOI
  95. [111]Mitomo S Maesawa C Ogasawara S Iwaya T Shibazaki M Yashima-Abo A Kotani K Oikawa H Sakurai E Izutsu N Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines Cancer Sci 99 280 286 2008 10.1111/j.1349-7006.2007.00666.x 18201269 PMC11159409 · DOI
  96. [112]Zhang D Xiao YF Zhang JW Xie R Hu CJ Tang B Wang SM Wu YY Hao NB Yang SM miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT Cancer Lett 360 151 159 2015 10.1016/j.canlet.2015.01.044 25662441 · DOI
  97. [113]Melnik BC miR-21: An environmental driver of malignant melanoma? J Transl Med 13 202 2015 10.1186/s12967-015-0570-5 26116372 PMC4482047 · DOI
  98. [114]Yang Y Yang JJ Tao H Jin WS MicroRNA-21 controls hTERT via PTEN in human colorectal cancer cell proliferation J Physiol Biochem 71 59 68 2015 10.1007/s13105-015-0380-5 25603978 · DOI
  99. [115]Nguyen DD Chang S Development of novel therapeutic agents by inhibition of oncogenic microRNAs Int J Mol Sci 19 pii E65 2017 10.3390/ijms19010065 29280958 PMC5796015 · DOI
  100. [116]Mizukoshi E Kaneko S Telomerase-targeted cancer immunotherapy Int J Mol Sci 20 pii E1823 2019 10.3390/ijms20081823 31013796 PMC6515163 · DOI
  101. [117]Staff C Mozaffari F Frödin JE Mellstedt H Liljefors M Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients Int J Oncol 45 1293 1303 2014 10.3892/ijo.2014.2496 24919654 · DOI
  102. [118]Fenoglio D Traverso P Parodi A Tomasello L Negrini S Kalli F Battaglia F Ferrera F Sciallero S Murdaca G A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer Cancer Immunol Immunother 62 1041 1052 2013 10.1007/s00262-013-1415-9 23591981 PMC11029691 · DOI
  103. [119]Fenoglio D Parodi A Lavieri R Kalli F Ferrera F Tagliamacco A Guastalla A Lamperti MG Giacomini M Filaci G Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one Hum Vaccin Immunother 11 838 850 2015 10.1080/21645515.2015.1012032 25714118 PMC4514186 · DOI
  104. [120]Lilleby W Gaudernack G Brunsvig PF Vlatkovic L Schulz M Mills K Hole KH Inderberg EM Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer Cancer Immunol Immunother 66 891 901 2017 10.1007/s00262-017-1994-y 28391357 PMC11028648 · DOI
  105. [121]Kotsakis A Papadimitraki E Vetsika EK Aggouraki D Dermitzaki EK Hatzidaki D Kentepozidis N Mavroudis D Georgoulias V A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide Lung Cancer 86 59 66 2014 10.1016/j.lungcan.2014.07.018 25130084 · DOI
  106. [122]Su Z Dannull J Yang BK Dahm P Coleman D Yancey D Sichi S Niedzwiecki D Boczkowski D Gilboa E Vieweg J Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer J Immunol 174 3798 3807 2005 10.4049/jimmunol.174.6.3798 15749921 · DOI · Paper page
  107. [123]Khoury HJ Collins RH Jr Blum W Stiff PS Elias L Lebkowski JS Reddy A Nishimoto KP Sen D Wirth ED III Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia Cancer 123 3061 3072 2017 10.1002/cncr.30696 28411378 · DOI · Paper page
  108. [124]Galati D Zanotta S Empowering dendritic cell cancer vaccination: The role of combinatorial strategies Cytotherapy 20 1309 1323 2018 10.1016/j.jcyt.2018.09.007 30360963 · DOI
  109. [125]Salazar-Onfray F Pereda C Reyes D López MN TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer Biol Res 46 431 440 2013 10.4067/S0716-97602013000400014 24510145 · DOI
  110. [126]Thalmensi J Pliquet E Liard C Escande M Bestetti T Julithe M Kostrzak A Pailhes-Jimenez AS Bourges E Loustau M Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response Oncoimmunology 5 e1083670 2016 10.1080/2162402X.2015.1083670 27141336 PMC4839321 · DOI
  111. [127]Yan J Pankhong P Shin TH Obeng-Adjei N Morrow MP Walters JN Khan AS Sardesai NY Weiner DB Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity Cancer Immunol Res 1 179 189 2013 10.1158/2326-6066.CIR-13-0001 24777680 PMC4096936 · DOI
  112. [128]Ohta R Demachi-Okamura A Akatsuka Y Fujiwara H Kuzushima K Improving TCR affinity on 293T cells J Immunol Methods 466 1 8 2019 10.1016/j.jim.2018.11.010 30468736 · DOI
  113. [129]Jordheim LP Durantel D Zoulim F Dumontet C Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases Nat Rev Drug Discov 12 447 464 2013 10.1038/nrd4010 23722347 · DOI
  114. [130]Pascolo E Wenz C Lingner J Hauel N Priepke H Kauffmann I Garin-Chesa P Rettig WJ Damm K Schnapp A Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate J Biol Chem 277 15566 15572 2002 10.1074/jbc.M201266200 11854300 · DOI
  115. [131]Kim MY Vankayalapati H Shin-Ya K Wierzba K Hurley LH Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex J Am Chem Soc 124 2098 2099 2002 10.1021/ja017308q 11878947 · DOI
  116. [132]Gomez DL Armando RG Cerrudo CS Ghiringhelli PD Gomez DE Telomerase as a cancer target. Development of new molecules Curr Top Med Chem 16 2432 2440 2016 10.2174/1568026616666160212122425 26873194 PMC4997958 · DOI
  117. [133]Nemunaitis J Tong AW Nemunaitis M Senzer N Phadke AP Bedell C Adams N Zhang YA Maples PB Chen S A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors Mol Ther 18 429 434 2010 10.1038/mt.2009.262 19935775 PMC2839300 · DOI
  118. [134]Schepelmann S Ogilvie LM Hedley D Friedlos F Martin J Scanlon I Chen P Marais R Springer CJ Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2 Cancer Res 67 4949 4955 2007 10.1158/0008-5472.CAN-07-0297 17510425 · DOI
  119. [135]Picard D Intracellular dynamics of the Hsp90 co-chaperone p23 is dictated by Hsp90 Exp Cell Res 312 198 204 2006 10.1016/j.yexcr.2005.10.009 16289154 · DOI
  120. [136]Ning X Yang S Wang R Zhang R Guo L Tie J Cheng Y Wang G Wan S Fang D POT1 deficiency alters telomere length and telomere-associated gene expression in human gastric cancer cells Eur J Cancer Prev 19 345 351 2010 10.1097/CEJ.0b013e32833b4812 20517159 · DOI
  121. [137]Ganesan K Xu B Telomerase inhibitors from natural products and their anticancer potential Int J Mol Sci 19 pii E13 2017 10.3390/ijms19010013 29267203 PMC5795965 · DOI
  122. [138]Mizushina Y Takeuchi T Sugawara F Yoshida H Anti-cancer targeting telomerase inhibitors: β-rubromycin and oleic acid Mini Rev Med Chem 12 1135 1143 2012 10.2174/138955712802762220 22876944 · DOI
  123. [139]Smith S Telomerase can't handle the stress Genes Dev 32 597 599 2018 10.1101/gad.316042.118 29802121 PMC6004074 · DOI

Cited by

See all 119

Metadata

Authors
Trybek, T., Kowalik, A., Góźdź, S., & Kowalska, A.
Affiliations
  • Endocrinology Clinic, Holycross Cancer Center, 25‑734 Kielce, Poland
  • Department of Molecular Diagnostics, Holycross Cancer Center, 25‑734 Kielce, Poland
  • The Faculty of Health Sciences, Jan Kochanowski University, 25‑319 Kielce, Poland
ORCID
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2020-05-21
Volume
20
Issue
2
Pages
1015-1027
ISSN
  • 1792-1074
  • 1792-1082
DOI
10.3892/ol.2020.11659
PMC
PMC7377093
Cited by
119
References
15

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review